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Most previous studies have found no effects of cyclo-
sporin A and FK-506 on active oxygen generation in
human polymorphonuclear leukocytes. Recently
various differences in biologic properties have been
reported between unprimed peripheral blood human
polymorphonuclear leukocytes and tissue or primed
human polymorphonuclear leukocytes. In this study,
we investigated the effects of cyclosporin A and FK-
506 on superoxide (O2
±) generation induced by the
chemotactic peptide N-formyl-L-methionyl-L-leucyl-
L-phenylalanine in human peripheral blood poly-
morphonuclear leukocytes primed or unprimed with
tumor necrosis factor a. Neither cyclosporin A nor
FK-506 suppressed N-formyl-L-methionyl-L-leucyl-
L-phenylalanine-induced O2
± generation in unprimed
human polymorphonuclear leukocytes at concentra-
tions between 0.1 nM and 10 mM, as in previous stu-
dies. Only at 1 mM of cyclosporin A and 100 nM of FK-
506 were marginal suppressive effects observed. On
the other hand, cyclosporin A and FK-506 both
suppressed N-formyl-L-methionyl-L-leucyl-L-phe-
nylalanine-induced O2
± generation in tumor-necrosis-
factor-a-primed human polymorphonuclear leuko-
cytes, strongly and dose dependently, at concentra-
tions between 1 nM and 1 mM. Neither cyclosporin A
nor FK-506 in¯uenced tyrosyl phosphorylation of 115
kDa protein, which is inducible during the priming
process, suggesting that neither cyclosporin A nor FK-
506 in¯uenced the tumor-necrosis-factor-a-induced
priming process itself, and instead modi®ed the bio-
logic response of primed human polymorphonuclear
leukocytes. Key words CBL/priming. J Invest Dermatol
115:986±989, 2000
A
ctive oxygen (superoxide anion) derived from
polymorphonuclear leukocytes (PMNL) plays crucial
roles in host defense mechanisms against microbes
and in the pathogenesis of in¯ammatory processes
such as psoriasis vulgaris, Behcet's disease, and
vesiculobullous and pustular diseases (Malech and Gallin, 1987;
Kapp and Zeck-Kapp, 1990).
Immunosuppressive agents such as cyclosporin A (CsA) and FK-
506 are effective in treating these diseases. Suppressive effects of
these agents on lymphocyte and cytokine activities have been well
investigated (Sigal and Dumont, 1992; Kono et al, 1995). The
effects of CsA and FK-506 on active oxygen derived from PMNL,
however (Janco and English, 1983; Wenzel-Seifert and Seifert,
1993), and biologic properties of PMNL (Weinbaum et al, 1984;
Nielsen et al, 1986; Forrest et al, 1991; Di Stefano et al, 1994) are
controversial. Most authors using PMNL derived from peripheral
blood of healthy volunteers have found no effects of these agents on
PMNL in in vitro studies. On the other hand, several authors have
reported suppressive effects of CsA and FK-506 on O2
± generation
and chemotaxis of PMNL derived from psoriatic patients (Pigatto
et al, 1988; Schopf et al, 1992). In in vivo studies, suppression of O2±
formation of PMNL by CsA and FK-506 in ischemic injury of rat
liver (Tatsuma et al, 1994) and of cat intestine (Kubes et al, 1991)
has been reported. The reasons for the discrepancy in ®ndings
described above have not yet been determined.
Circulating PMNL migrate into tissues and are primed there by
various ligands, such as lipopolysaccharides, tumor necrosis factor a
(TNF-a), and other cytokines. Differences in biologic and
biochemical properties have been reported between primed and
unprimed PMNL (Yamamoto et al, 1991; Hallett and Lloyds,
1995). We previously reported that priming with TNF-a, by
incubation for 10 min at 37°C, made peripheral blood PMNL as
potent as tissue PMNL (Akimaru et al, 1992; Sato et al, 1996).
TNF-a was found in the lesions of atopic dermatitis and psoriasis
(Kapp et al, 1990). Circulating PMNL migrate into such lesions and
would be primed there by TNF-a and other cytokines. It is
possible, however, that PMNL derived from peripheral blood of
healthy volunteers, which have been used in the experiments by
almost all researchers, were unprimed.
In this study, we investigated the effects of CsA and FK-506 on
superoxide anion (O2±) generation induced by the chemotactic
peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMet-
Leu-Phe, fMLP) in human peripheral blood PMNL primed or
unprimed with TNF-a. We also studied the effects of CsA and FK-
506 on tyrosyl phosphorylation of 115 kDa protein in TNF-a-
primed PMNL, which is reported to be a phosphotyrosine kinase-
related protein (Cbl) and to be induced during the priming process
(Akimaru et al, 1992; Naccache et al, 1997).
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MATERIALS AND METHODS
Reagents and chemicals CsA and FK-506 were kindly provided by
Novartis (Basel, Switzerland) and Fujisawa Pharmaceutical (Osaka, Japan),
respectively. Stock solutions of CsA and FK506 (1 mM) were prepared in
100% (vol/vol) dimethyl sulfoxide (DMSO) and were kept in
polypropylene tubes at ±20°C protected from light for up to 4 wk. The
CsA and FK-506 solutions were diluted immediately before experiments.
The ®nal concentration of DMSO in all experiments was adjusted to 0.1%
(vol/vol). TNF-a was kindly provided by Hayashibara Institute (Okayama,
Japan). TNF-a was diluted with double-distilled water with 0.2 mg per ml
albumin and stored in polypropylene tubes at 4°C protected from light for
up to 3 mo. Mono Poly solution was obtained from Dainippon
Pharmaceutical (Tokyo, Japan). PVDF membranes were purchased from
Millipore. Anti-phosphotyrosine antibody (PY-20) and ECL (+) were
obtained from Amersham Pharmacia Biotech. DMSO, fMLP,
ferricytochrome c, superoxide dismutase, trichloroacetic acid, Triton
X100, dithiothreitol (DTT), LiDS, bovine serum albumin, Tween 20,
and other agents were purchased from Sigma (St. Louis, MO) and Wako
Chemical (Tokyo, Japan).
Isolation of PMNL Isolation of PMNL was performed as described in a
previous report (Akimaru et al, 1992; Sato et al, 1996). Fresh venous blood
was kindly donated by healthy volunteers (26±40 y of age) who had taken
no drugs and had not smoked for at least 1 mo. PMNL were isolated from
the fresh venous blood with 0.38% (vol/vol) sodium citrate. Four milliliters
of the blood sample were layered on 3 ml Mono Poly solution in 12 ml
polypropylene tubes. The tubes were centrifuged at 400g for 25 min at
25°C. The second layer was PMNL. They were suspended in Krebs-
Ringer phosphate buffer (KRP) solution and centrifuged at 400g for 5 min
at 4°C twice. Cell preparations (> 98% viable neutrophils by trypan blue
dye exclusion test) were adjusted to a density of 106 cells per 10 ml of KRP
solution, at pH 7.4.
Measurement of O2
± generation Superoxide generation was assayed
by the cytochrome c reduction method according to Seifert et al (1989)
with some modi®cations (Akimaru et al, 1992; Sato et al, 1996). It was
monitored at 550 nm by continuous measurement of ferricytochrome c
reduction, using an UV-3100 dual-beam spectrophotometer (Shimazu,
Tokyo, Japan). The reaction mixture contained, in a ®nal volume of 2 ml
KRP, 1 mM CaCl2, 20 mM ferricytochrome c, and 10 mM glucose.
Superoxide generation was calculated from the rate of superoxide-
dismutase-inhibitable reduction of ferricytochrome c.
In vivo, circulating PMNL encounter CsA or FK-506 in the peripheral
blood, migrate into tissue, and are exposed to TNF-a there. Therefore, in
this study, PMNL were treated with CsA or FK-506 ®rst and then
incubated with TNF-a for priming. In our previous studies, 10 units per ml
of TNF-a was found to be suf®cient to make circulating PMNL as potent
as tissue PMNL (Akimaru et al, 1992; Sato et al, 1996). PMNL (2 3 106
cells) were suspended in the reaction mixture and were incubated for 2 min
at 37°C in the presence or absence of CsA or FK-506 (®nal concentration
0.1 nM-1 mM). Then TNF-a (10 units per ml) or solvent was added and
the mixture was incubated for 10 min at 37°C for priming.
Superoxide generation was initiated by the addition of fMLP (®nal
concentration 50 nM) and was measured. Superoxide dismutase was added
to the sample (®nal concentration 15 mg per ml) as a standard. Kapp et al
(1990) reported direct stimulation of the oxidative burst by TNF-a in
human PMNL at a higher concentration (1000±10,000 units per ml) and
longer incubation time (60±180 min). In this study, TNF-a itself (10 units
per ml, 10 min) had no effect on O2± generation in either unprimed or
primed PMNL. In our experimental system, viabilities of PMNL with CsA,
FK-506, and TNF-a, as assayed by the trypan blue dye exclusion test, were
over 95% for 1 h after harvest.
Detection of phosphorylated tyrosine residues in PMNL
proteins The method used for assay of tyrosine kinase has been
described elsewhere (Akimaru et al, 1992). PMNL (106 cells) were
suspended in 1 ml KRP solution and incubated for 3 min at 37°C in 2 ml
polypropylene tubes. One microliter of CsA, FK-506 was added (1 nM-
10 mM) and the mixture was incubated for 2 min at 37°C. TNF-a (10 units
per ml) or solvent was added and the mixture was incubated for another
10 min at 37°C. Then, 500 ml of 45% trichloroacetic acid was added and the
mixture was incubated for another 10 min at 4°C. After centrifugation at
2000g for 5 min at 4°C, 40 ml of urea/Triton X100/DTT solution, 10 ml of
10% LiDS, and 2 ml of 1 M Tris were added to the precipitates with
sonication. Western blotting was then performed. PVDF membrane was
blocked by 3% bovine serum albumin with TBS-T solution containing
NaCl, Tween 20, and methanol for 1 h at room temperature. The
membrane was washed brie¯y with TBS-T solution. Then, 0.1% PY-20
was added to the membrane and incubated for 1 h at room temperature.
The membrane was washed for 15 min and 5 min twice with TBS-T
solution. Peroxidase-positive bands were detected using the ECL (+)
Western blotting detection system (Amersham). After staining with
Coomassie brilliant blue, molecular weights of proteins were determined
using Daiichi-Kagaku standards. Tyrosyl phosphorylation of 115 kDa
protein in PMNL primed with TNF-a was quantitatively assayed using a
densitometric method with NIH image (version 1.61).
Statistical analysis Comparisons between groups were performed using
Student's t test.
RESULTS
Effects of CsA and FK-506 on O2
± formation by TNF-a-
primed PMNL The effects of CsA and FK-506 on fMLP-
induced O2± formation in TNF-a-primed PMNL (10 units per ml,
10 min at 37°C) were examined (Fig 1A). In TNF-a-primed
PMNL, O2± formation was instantaneously and very markedly
induced by fMLP, as we previously reported (Sato et al, 1996). CsA
dose-dependently suppressed O2± formation at concentrations over
1 nM. It inhibited O2± formation by about 20% at a concentration
of 1 nM, by about 30% at 10 nM, and by about 50% at 100 nM.
Figure 1. Concentration-response function for fMLP-induced O2
± generation in unprimed and TNF-a-primed human PMNL: effects of
CsA and FK-506. (A, B) Unprimed human PMNL; (A) TNF-a-primed human PMNL. For unprimed PMNL, CsA (s), FK-506 (d) (®nal concentration
0.01 nM±1 mM), or solvent (control) was added to the reaction mixture 12 min before fMLP stimulation (A, B). For primed PMNL, CsA (h), FK-506 (j)
(®nal concentration 0.01 nM±1 mM), or solvent (control) was added to the reaction mixture 2 min before addition of 10 units per ml of TNF-a or solvent
alone. After 10 min priming with TNF-a, fMLP was added (A). To precisely determine the effects in unprimed PMNL, the graphs for unprimed cells were
magni®ed in scale for the vertical axis (B). Values are the means of assays (n = 5 or 6) of an experiment performed with six preparations of PMNL. Bars, SD;
*p < 0.05; **p < 0.01.
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The rate of suppression was about 70% at a concentration of 1 mM.
The concentration of CsA required for 50% inhibition (IC50) was
80.3 nM. FK-506 also dose-dependently suppressed O2± formation
at concentrations over 1 nM. FK-506 and CsA each suppressed O2±
formation to the same extent at concentrations between 1 nM and
1 mM. The rate of suppression by each was 65% at a concentration
of 1 mM. The IC50 of FK-506 was 87.1 nM.
Effects of CsA and FK-506 on O2
± formation by unprimed
PMNL In unprimed PMNL, O2
± formation was induced
instantaneously by 50 nM fMLP, as we previously reported (Sato
et al, 1996). Compared with TNF-a-primed PMNL, the induction
of O2± formation by fMLP in unprimed PMNL was not strong
(Fig 1A). For precise analysis, the graphs for unprimed cells were
magni®ed in scale for the vertical axis (Fig 1B). The effects of CsA
and FK-506 on O2± formation induced by fMLP at 37°C in
unprimed PMNL were studied. CsA was not effective in
controlling O2
± formation. Though O2
± formation appeared to
be dose-dependently suppressed by CsA, the rates of suppression
were not signi®cant. Only doses of CsA and FK-506 above 1 mM
suppressed fMLP-induced O2± formation in unprimed PMNL. The
suppressions observed were signi®cant (p < 0.05), but marginally so
(by about 5.0%).
Effects of CsA and FK-506 on tyrosyl phosphorylation in
PMNL Tyrosyl phosphorylation induced by priming with TNF-
a (10 units per ml, 10 min at 37°C) in PMNL was detected by
immunoblotting with antiphosphotyrosine antibody. Consistent
with our previous observations (Akimaru et al, 1992),
phosphorylated tyrosines were detected in PMNL proteins with
molecular weights of 115, 108, 83, 72, 63, 53, 43 kDa and others
(Fig 2). On incubation with TNF-a, phosphorylation of those
proteins was increased. The CsA-treated PMNL demonstrated the
same pattern of tyrosyl phosphorylation (data not shown). As a
critical role of 115 kDa protein in the mechanism of priming of
PMNL has been reported (Akimaru et al, 1992; Naccache et al,
1997), tyrosyl phosphorylation of 115 kDa protein in PMNL
primed with TNF-a was assayed quantitatively, using a computed
densitometric method (Fig 3). At concentrations between 1 nM
and 1 mM, CsA had no effect on tyrosyl phosphorylation of 115
kDa protein. Although FK-506 appeared to inhibit tyrosyl
phosphorylation in the same range of concentrations, its rates of
inhibition were not statistically signi®cant. CsA and FK-506
particularly inhibited tyrosyl phosphorylation of the 115 kDa
protein only at higher concentration. CsA inhibited the
phosphorylation of 115 kDa protein only at 10 mM, by 61.3%
(p < 0.01). FK-506 inhibited the phosphorylation of 115 kDa
protein by about 68.7% at 1 mM and by about 28.3% at 10 mM
(p < 0.01).
DISCUSSION
Recently various differences between primed or tissue PMNL and
unprimed PMNL derived from peripheral blood have been
reported (Yamamoto et al, 1991; Akimaru et al, 1992; Hallett and
Lloyds, 1995; Sato et al, 1996). As PMNL in lesional tissue
encounter TNF-a and other cytokines (Kapp et al, 1990),
experiments using primed PMNL re¯ect in vivo conditions more
than those with unprimed PMNL.
In this study, neither CsA nor FK-506 suppressed fMLP-induced
O2
± generation in unprimed PMNL at concentrations between
0.01 nM and 100 mM. Only at 1 mM of CsA and 100 nM of FK-506
were marginal suppressive effects observed. On the other hand, in
TNF-a-primed PMNL, both CsA and FK-506 suppressed fMLP-
induced O2
± generation, strongly and dose dependently, at
concentrations between 1 nM and 1 mM. CsA and FK-506
inhibited O2± generation to the same degree, and did so dose
dependently. Although the IC50 of CsA is 80.3 nM in the
therapeutic concentration range (125±375 nM) (Di Padova,
1989), the IC50 of FK-506 is 87.1 nM and supratherapeutic
(Starzl et al, 1989). CsA thus appears to be slightly more potent in
suppressing O2
± generation than FK-506.
Our ®ndings demonstrate a clear difference in biologic responses
between unprimed and primed PMNL, and suggest the signi®cance
of the priming process of PMNL. Previous researchers employed
unprimed PMNL derived from peripheral blood. Janco and English
(1983) and Chiara et al (1991) reported that CsA did not suppress
PMA-stimulated O2± generation even at 1 mg per ml. Kharazmi et al
(1985) reported that CsA did not inhibit opsonized zymosan-
stimulated oxidative burst at a therapeutic concentration. Starzl et al
(1989) reported that FK-506 did not suppress fMLP-induced O2±
generation. Our ®ndings revealed no suppressive effects of CsA or
FK-506 on fMLP-induced O2± generation in unprimed PMNL at
concentrations between 0.01 and 100 nM. These ®ndings recon-
®rmed those of previous studies.
Wenzel-Seifert et al also detected no effect of 1±100 nM of CsA
or FK-506 on O2
± generation in unprimed PMNL. They reported
that CsA and FK-506 inhibited fMLP-induced O2± generation in
unprimed PMNL, however, by about 53% and 30%, respectively,
at concentrations over 1 mM (Wenzel-Seifert et al, 1991; Wenzel-
Figure 2. Effect of FK-506 on tyrosyl phosphorylation of PMNL
protein. After incubation of PMNL (2 3 106 cells) with FK-506 or solvent
for 2 min and TNF-a 10 units per ml for 10 min, neutrophil proteins were
subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis
followed by transfer to PVDF membrane. Tyrosine residues in phosphory-
lated proteins were detected by immunoblotting with antiphosphotyrosine
antibody. Lane 1, without TNF-a or FK-506; lanes 2±7, with 10 units
per ml of TNF-a; lanes 3±7, with 10 units per ml of TNF-a and FK-506;
lane 3, 10±9 M of FK-506; lane 4, 10±8 M; lane 5, 10-7 M; lane 6, 10±6 M; lane
7, 10±5 M.
Figure 3. Concentration-response function for tyrosyl phosphory-
lation of 115 kDa protein in human PMNL primed with TNF-a:
effects of CsA and FK-506. CsA (s) (®nal concentration 1 nM-10 mM),
FK-506 (d) (®nal concentration 1 nM-10 mM), or solvent (control) was
added to the reaction mixture 2 min before addition of 10 units per ml of
TNF-a or solvent alone. After 10 min priming with TNF-a, cells were
harvested and tyrosyl phosphorylation of 115 kDa protein was assayed as
described in Materials and Methods. Values are the means of assays (n = 6) of
an experiment performed with ®ve preparations of PMNL. Bars, SD;
*p < 0.01.
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Seifert and Seifert, 1993). In this study, O2± formation was found to
be suppressed at higher concentrations (100 nM for FK-506 and
1 mM for CsA), as reported by Wenzel-Seifert et al. The suppressive
effects of CsA and FK-506 on O2± generation in unprimed PMNL
were marginal, however, and only about 5% in this study. The
therapeutic concentrations of CsA and FK-506 are reported to be
125±375 nM (Di Padova, 1989) and 0.1±1 nM (Starzl et al, 1989),
respectively. The suppressive concentrations of 100 nM-1 mM
employed by Wenzel-Seifert et al were far higher than those
achieved therapeutically in human blood and in fact suprather-
apeutic and toxic. Although the cell viability assayed by the dye
exclusion test during the experiment was over 95%, as noted in
Materials and Methods, the possibility that the marginal suppressive
effects found in this study were the result of cytotoxic effects of
CsA and FK-506 cannot be excluded.
In contrast to previous studies using peripheral blood PMNL
derived from healthy volunteers, several authors have reported the
suppressive effects of CsA on O2± generation. Pigatto et al (1988)
and Schopf et al (1992) reported that CsA suppressed chemotaxis of
PMNL derived from psoriatic patients. On the other hand, in in
vivo studies, Tatsuma et al (1994), for example, reported suppression
of O2
± by CsA in ischemic injury of rat liver and Kubes et al (1991)
reported effects of CsA and FK-506 on O2± generation in cat
intestine. In pathologic conditions, PMNL might be nearly primed
by certain cytokines in the peripheral blood or in the lesional tissue
(Kapp et al, 1990). Our ®ndings may provide clues to resolving the
discrepancies in the ®ndings noted above.
Recently, several authors have reported that Cbl, a phosphotyr-
osine kinase-related 115 kDa protein, plays an important role in the
priming process of PMNL (Akimaru et al, 1992; Naccache et al,
1997). To clarify the reasons for this ®nding, the effects of CsA and
FK-506 on tyrosyl phosphorylation in PMNL protein were
investigated. We found little effect of CsA or FK-506 on
phosphorylation in PMNL at concentrations between 1 nM and
1 mM, however. Only at a higher concentration (10 mM) were
inhibitory effects of CsA and FK-506 found, especially on tyrosyl
phosphorylation of 115 kDa protein. As 10 mM of CsA and FK-506
are supratherapeutic concentrations (Di Padova, 1989; Starzl et al,
1989), the suppression of tyrosine phosphorylation of 115 kDa
protein may have been a toxic effect. These ®ndings suggest that
TNF-a-induced tyrosyl phosphorylation played no role in the
suppression of O2± generation by CsA and FK-506, and that neither
CsA nor FK-506 in¯uenced the TNF-a-induced priming process
itself. Instead, it is possible that CsA and FK-506 modi®ed the
biologic responses of primed PMNL. At present the mechanisms of
effects of CsA and FK-506 on O2± generation in TNF-a-primed
PMNL are not known in detail, but warrant further investigation.
In summary, this study showed that CsA and FK-506 suppressed
O2± generation in primed PMNL but not in unprimed PMNL. Our
®ndings suggest that CsA and FK-506 did not in¯uence the
priming process itself but did modulate the postpriming process.
The authors thank Dr. Masayasu Inoue (Professor and Chairman, The First
Department of Biochemistry, Osaka City University Medical School) and Dr.
Michael Connolly (Translation Center Inc., Osaka, Japan).
REFERENCES
Akimaru K, Utumi T, Sato EF, Klostergaard J, Inoue M, Utumi K: Role of tyrosyl
phosphorylation in neutrophil priming by tumor necrosis factor-a and
granulocyte colony stimulating factor. Arch Biochem Biophys 298:703±709, 1992
Chiara MD, Foot ABM, Sobrino F, Jones OTG: Differential effect of cyclosporine A
on respiratory burst by several types of human leukocytic cells. Biochem Int
23:1185±1193, 1991
Di Padova FE: Pharmacology of cyclosporine (Sandimmune) V. Pharmacological
effects on immune function: in vitro studies. Pharmacol Rev 41:373, 1989
Di Stefano R, Scavuzzo A, Pietrabissa A, et al: Effect of immunosuppressive regimens
on neutrophil chemotaxis. Transplant Proc 26:2861±2862, 1994
Forrest MJ, Jewell ME, Koo GC, Sigal NH: FK-506 and cyclosporin A: selective
inhibition of calcium ionophore-induced polymorphonuclear leukocyte
degranulation. Biochem Pharmacol 42:1221±1228, 1991
Hallett MB, Lloyds D: Neutrophil priming: the cellular signals that say `amber' but
not `green'. Immunol Today 16:264±268, 1995
Janco RL, English D: Cyclosporine and human neutrophil function. Transplantation
35:501±503, 1983
Kapp A, Zeck-Kapp G: Activation of the oxidative metabolism in human
polymorphonuclear neutrophilic granulocytes: the role of
immunomodulating cytokines. J Invest Dermatol 95 (Suppl.):94S±99S, 1990
Kapp A, Textor A, Krutmann J, Mueler A: Immunomodulating cytokines in atopic
dermatitis and psoriasis: production of tumour necrosis factor and
lymphotoxins by mononuclear cells in vitro. Br J Dermatol 122:587±592, 1990
Kharazmi A, Svenson M, Nielsen H, Birgens HS: Effect of cyclosporine A on human
neutrophil and monocyte function. Scand J Immunol 21:585±591, 1985
Kono T, Kondo S, Vennor TJ, Sauder DN, McKenzie RC: Inhibition of cytokine
gene expression in mouse skin by subcutaneous injection of cyclosporine. Skin
Pharmacol 8:149±155, 1995
Kubes P, Hunter J, Granger N: Effects of cyclosporine A and FK506 on ischemia/
reperfusion-induced neutrophil in®ltration in the cat. Digestive Dis Sci 36:1469±
1472, 1991
Malech HL, Gallin JI: Neutrophils in human diseases. N Engl J Med 317:687±694,
1987
Naccache PH, Gilbert C, Barab F, Al Shami A, Mahana W, Bourgoin SG: Agonist-
speci®c tyrosine phosphorylation of Cbl in human neutrophils. J Leucoc Biol
62:901±910, 1997
Nielsen OH, Bukhave K, Ahnfelt-Roenne I, Elmgreen J: Arachidonic acid
metabolism in human neutrophils: lack of effect of cyclosporine A. Int J
Immunopharmacol 8:419±426, 1986
Pigatto PD, Mozzanica N, Polenghi MM, Altomare GF, Finzi AF: Cyclosporine A
inhibits polymorphonuclear leukocyte chemotaxis in vivo. Transplant Proc 3
(Suppl. 4):91±94, 1988
Sato EF, Utsumi K, Inoue M: Human oral neutrophils: isolation and characterization.
Meth Enzymol 268 (3±2578):503±509, 1996
Schopf RE, Hoecher J, Rehder M, Faerber L, Morsches B: Etretinate or cyclosporin-
A treatment normalizes the enhanced respiratory burst of polymorphonuclear
leukocytes in psoriasis. Arch Dermatol Res 284:227±231, 1992
Seifert R, Burde R, Schultz G: Lack of opioid peptides, morphine and naloxan on
superoxide formation in human neutrophils and HL-60 leukemic cells.
Naunyn-SchmiedebergõÂs Arch Pharmacol 340:101±106, 1989
Sigal NH, Dumont FJ: Cyclosporin A, FK-506, and rapamycin: pharmacologic
probes of lymphocytes signal transduction. Ann Rev Immunol 10:519±560, 1992
Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A: FK-506 for liver,
kidney and pancreas transplantation. Lancet ii:1000±1004, 1989
Tatsuma T, Kim YI, Ono M, Kai T, Ishii T, Akizuki S, Kobayashi M: Suppression of
superoxide production from polymorphonuclear leukocytes by cyclosporine in
ischemia-reperfusion of the liver. Transplant Proc 26:2413±2416, 1994
Weinbaum DL, Kaplan SS, Zdziarski U, Rinaldo CR Jr, Schroeder KK: Human
polymorphonuclear leukocyte interaction with cyclosporine A. Infect Immun
43:791±794, 1984
Wenzel-Seifert K, Seifert R: Partial inhibition of human neutrophil activation by
FK-506 at supratherapeutic concentrations. Naunyn-SchmiedebergõÂs Arch
Pharmacol 348:7±13, 1993
Wenzel-Seifert K, Gruenbaum L, Seifert R: Differential inhibition of human
neutrophil activation by cyclosporin A, D, and H. Cyclosporin H is a potent
and effective inhibitor of formyl peptide-induced superoxide formation. J
Immunol 147:1940±1946, 1991
Yamamoto M, Saeki K, Utsumi K: Isolation of human salivary polymorphonuclear
leucocytes and their stimulation-coupled responses. Arch Biochem Biophys
289:76±82, 1991
VOL. 115, NO. 6 DECEMBER 2000 CSA AND FK-506 ON PMNL PRIMED BY TNF-a 989
